PNC Financial Services Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-1,007
| Closed | -$11K | – | 4370 |
|
|
2017
Q3 | $11K | Buy |
1,007
+510
| +103% | +$5.63K | ﹤0.01% | 3661 |
|
|
2017
Q2 | $5K | Buy |
497
+164
| +49% | +$1.64K | ﹤0.01% | 3838 |
|
|
2017
Q1 | $3K | Buy |
333
+311
| +1,414% | +$3.11K | ﹤0.01% | 3903 |
|
|
2016
Q4 | $0 | Buy |
+22
| New | +$220 | ﹤0.01% | 4187 |
|
|
2016
Q3 | – | Sell |
-328
| Closed | -$4K | – | 4511 |
|
|
2016
Q2 | $4K | Sell |
328
-57
| -15% | -$747 | ﹤0.01% | 3987 |
|
|
2016
Q1 | $4K | Buy |
385
+13
| +3% | +$116 | ﹤0.01% | 3984 |
|
|
2015
Q4 | $3K | Hold |
372
| – | – | ﹤0.01% | 4091 |
|
|
2015
Q3 | $3K | Sell |
372
-18
| -5% | -$154 | ﹤0.01% | 4212 |
|
|
2015
Q2 | $4K | Buy |
390
+184
| +89% | +$1.68K | ﹤0.01% | 4218 |
|
|
2015
Q1 | $2K | Hold |
206
| – | – | ﹤0.01% | 4373 |
|
|
2014
Q4 | $2K | Buy |
+206
| New | +$1.67K | ﹤0.01% | 3879 |
|
|
2013
Q4 | – | Sell |
-2,374
| Closed | -$12K | – | 3697 |
|
|
2013
Q3 | $12K | Sell |
2,374
-369
| -13% | -$2.06K | ﹤0.01% | 3201 |
|
|
2013
Q2 | $14K | Buy |
+2,743
| New | +$13.1K | ﹤0.01% | 2950 |
|
PNC Financial Services Group's SCLN Position: Q4 2017 in Review
PNC Financial Services Group sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 1,007 shares — an estimated $11K sold.
PNC Financial Services Group first reported a position in SCLN in Q2 2013 and held it in 13 quarters. The position peaked at $14K in Q2 2013. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- PNC Financial Services Group reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- PNC Financial Services Group sold 1,007 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $11K.
- PNC Financial Services Group first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 13 quarters.
- PNC Financial Services Group's Sciclone Pharmaceuticals Inc position peaked at $14K in Q2 2013.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on PNC Financial Services Group's 13F filing for Q4 2017, filed 9 Feb 2018.